Annotation Detail

Information
Associated Genes
ROS1
Associated Variants
ROS1 REARRANGEMENT ROS1 REARRANGEMENT
Associated Disease
colorectal adenocarcinoma
Source Database
CIViC Evidence
Description
A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Break apart FISH assay, which does not distinguish ROS1-fusion partner, was used on the tissue microarray to determine ROS1 fusion status. 2 cases of ROS1 fusions were found. 1 case was verified by RT-PCR to be a SLC34A2-ROS1 fusion, but this case was also positive for BRAF V600E. The second case of ROS1 fusion was of undetermined fusion partner, where known ROS1 fusion parters SLC34A2, CD74 and SDC4 were tested. This case did not have KRAS or BRAF mutations, indicating that ROS1 fusion may act in a small subset of colorectal cancer as a driver targetable by crizotinib or other inhibitors.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1301
Gene URL
https://civic.genome.wustl.edu/links/genes/4941
Variant URL
https://civic.genome.wustl.edu/links/variants/269
Rating
2
Evidence Type
Predictive
Disease
Colorectal Adenocarcinoma
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
E
Clinical Significance
Sensitivity/Response
Pubmed
24296758
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue